Xeris Pharmaceuticals (XERS) financial statements
Xeris Pharmaceuticals reported revenue of $292M in fiscal 2025, up 70.7% a year over 5 years.
Net income was $554,000 and the operating margin 8.5%, against -414.5% in 2020.
Free cash flow was $29M.
The diluted share count rose 305% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Xeris Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $20M | $50M | $110M | $164M | $203M | $292M |
| Cost of revenue | $9M | $13M | $23M | $29M | $37M | $43M |
| Gross profit | $11M | $36M | $88M | $135M | $166M | $249M |
| Research and development | $21M | $25M | $21M | $22M | $26M | $31M |
| Selling, general and admin | $74M | $126M | $138M | $146M | $163M | $182M |
| Operating income | -$84M | -$115M | -$82M | -$44M | -$34M | $25M |
| Interest expense | $11M | $7M | $14M | $27M | $30M | $29M |
| Pre-tax income | — | -$123M | -$96M | -$64M | -$57M | $554,000 |
| Income tax | -$110,000 | $0 | -$1M | -$1M | -$2M | $0 |
| Net income | -$91M | -$123M | -$95M | -$62M | -$55M | $554,000 |
| EPS (diluted) | -$2.14 | -$1.55 | -$0.70 | -$0.45 | -$0.37 | $0.00 |
| Diluted shares | 43M | 79M | 136M | 138M | 147M | 173M |
| Gross margin | 53.7% | 73.1% | 79.5% | 82.5% | 81.9% | 85.4% |
| Operating margin | -414.5% | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% |
| Net margin | -452.2% | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
Balance sheet
Fiscal years, from Xeris Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $134M | $102M | $122M | $72M | $72M | $111M |
| Receivables | $7M | $17M | $31M | $39M | $40M | $51M |
| Inventory | $8M | $18M | $25M | $39M | $48M | $69M |
| Total current assets | $152M | $143M | $187M | $156M | $168M | $240M |
| Property, plant and equipment | $7M | $7M | $6M | $6M | $6M | $5M |
| Goodwill | $0 | $23M | $23M | $23M | $23M | $23M |
| Total assets | $159M | $304M | $345M | $323M | $323M | $384M |
| Total current liabilities | $28M | $79M | $74M | $95M | $100M | $110M |
| Long-term debt | — | — | — | $191M | $217M | $220M |
| Total liabilities | $125M | $209M | $299M | $329M | $353M | $370M |
| Shareholders' equity | $34M | $95M | $45M | -$7M | -$30M | $14M |
| Net debt | -$38M | -$67M | -$122M | $123M | $160M | $109M |
Cash flow
Fiscal years, from Xeris Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$81M | -$96M | -$103M | -$47M | -$37M | $29M |
| Capital spending | $377,000 | $1M | -$524,000 | -$2M | -$868,000 | -$696,000 |
| Free cash flow | -$81M | -$97M | -$102M | -$45M | -$36M | $29M |
| Stock-based compensation | $8M | $11M | $12M | $11M | $18M | $22M |
| Net borrowing | $70M | $0 | $103M | $0 | $0 | — |
| Free cash flow margin | -401.6% | -194.8% | -92.9% | -27.3% | -17.8% | 10.0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for XERS.
Open XERS in InvestinglyQuestions
What was Xeris Pharmaceuticals's revenue in 2025?
$292M in fiscal 2025, from its 10-K filing.
How much free cash flow does Xeris Pharmaceuticals generate?
$29M in fiscal 2025 (operating cash flow minus capital spending).
From Xeris Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.